UroPharma is exploiting an innovative proprietary drug delivery technology, the Direct to Bladder (dtb) device, in order to administer ‘modified generic’ or novel drugs directly into the urinary bladder. This delivery route is known as ‘intravesical drug delivery’ and this new emerging market represents an exciting opportunity for targeted, personalized, healthcare for the company.
Bladder problems are on the increase with an aging population and conventional therapeutics is not reducing this healthcare cost. As pioneers in the field of intravesical bladder treatment, the company intends to meet this clinical challenge head-on and develop UroPharma into a driving force in this novel urinary therapeutics market. By following this important commercial and clinical agenda, the directors intend to build UroPharma into a dynamic business over the next five years, providing substantial future shareholder value.
The company’s mission is to develop novel drugs with delivery technology that will greatly reduce the cost burden to healthcare funders and services as well as substantially improving the quality of life of patients with bladder disorders.
This will be achieved by developing a range of therapeutic drugs based on patients’ needs and lifestyles, which will be delivered through this novel cost effective drug delivery system. The company anticipates an early product uptake as was experienced with the successful Atropine Study carried out by Professor Glickman et al, funded by the MS Society in 20071.